Observe Medical Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Observe Medical heeft een totaal eigen vermogen van NOK107.4M en een totale schuld van NOK56.0M, wat de schuld-eigenvermogensverhouding op 52.1% brengt. De totale activa en totale passiva bedragen respectievelijk NOK246.4M en NOK139.0M.

Belangrijke informatie

52.1%

Verhouding schuld/eigen vermogen

NOK 55.97m

Schuld

Rente dekkingsratio	n/a
Contant	NOK 2.70m
Aandelen	NOK 107.45m
Totaal verplichtingen	NOK 138.95m
Totaal activa	NOK 246.40m

Recente financiële gezondheidsupdates

Recent updates

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Jun 27

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Sep 23

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Jun 07

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Feb 08

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

Sep 11

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Mar 02

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NOK28.3M ) van OBSRV } dekken niet de korte termijn passiva ( NOK111.8M ).

Langlopende schulden: De kortetermijnactiva OBSRV ( NOK28.3M ) overtreffen de langetermijnschulden ( NOK27.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 49.6% ) OBSRV wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van OBSRV is de afgelopen 5 jaar gedaald van 161.6% naar 52.1%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: OBSRV heeft voldoende cash runway voor 2 maanden op basis van de laatst gerapporteerde vrije kasstroom, maar heeft sindsdien extra kapitaal opgehaald.

Voorspelling contante baan: Er wordt voorspeld dat OBSRV voldoende kasmiddelen zal hebben voor 1 maanden op basis van de vrije kasstroom schattingen, maar heeft sindsdien extra kapitaal opgehaald.

Observe Medical Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Recent updates

First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023)

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical Asa Announces CFO Changes

Full year 2023 earnings released: kr1.05 loss per share (vs kr1.08 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Chief Financial Officer exercised options to buy kr149k worth of stock.

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

New major risk - Share price stability

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Third quarter 2022 earnings released: kr0.28 loss per share (vs kr0.43 loss in 3Q 2021)

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Observe Medical ASA Announces Executive Appointments

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Full year 2021 earnings released: kr1.34 loss per share (vs kr2.22 loss in FY 2020)

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: kr29.80

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: kr16.00

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: kr14.70

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: kr11.40

New 90-day low: kr11.90

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: kr12.00

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: kr13.20

Earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven